Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Lowering HCV Drug List Prices With Authorized Generics

Executive Summary

Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.

You may also be interested in...



Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate

The CAR-T therapy’s sales declined 2% from the previous quarter, although EU sales are growing briskly. The HIV franchise posted its best quarter ever, but the company’s overall financial performance was flat.

A Case For List Price Cuts? Study Highlights Reduced 340B Liability For Hep C Drugs

Lower list prices for Epclusa, Harvoni, and Zepatier might actually boost revenue by reducing 340B discounts, but rebate-eschewing dynamic may not expand beyond them because of different exposures to 340B in other classes – and the pending HHS rebate rule.

What Will Happen When Rebates Go Away? Look At Authorized Generics

Recent launches by Lilly, Amgen and Gilead suggest list prices may decrease with the HHS proposal to disrupt the rebate system, but not as low as current net prices after rebates, according to pharmacy benefit experts.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS123941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel